$3.58▼-0.13 (-3.38%)
Extended:$3.50-0.08 (-2.10%)· 8:33 PM ET
11/21/26
ENDRA Life Sciences (NDRA)
Saturday
12:01 AM ET
ThesisPositive clinical trial results and potential partnerships are enhancing investor sentiment towards ENDRA, suggesting a favorable outlook for growth.
Revenue Outlook
What’s Driving the Stock
- 01Recent clinical trial results showed a 30% improvement in diagnostic accuracy compared to traditional methods, potentially increasing adoption rates.
- 02Partnership discussions with a major healthcare provider in the U.S. could lead to a significant distribution agreement, expanding market reach.
- 03Potential regulatory approval expected in Q3 2026, which could unlock new revenue streams and validate technology.
- 04Growth in non-invasive diagnostic technologies
- 05Increased focus on early disease detection
- 06Regulatory approvals for TAI technology in key markets
- 07Partnerships with healthcare providers or distributors
- 08Clinical trial results demonstrating efficacy and safety
FY2025 Snapshot
- Revenue
- $0.00
- Gross Margin
- 0.0%
- Op. Margin
- 0.0%
- Net Margin
- 0.0%
- Net Income
- $-7M
- NI Growth
- +38.9%
- EPS
- $-8.93
- 1Y Return
- -46.2%
NDRA Chart
My Notes
- "Our innovative technology is on the brink of transforming diagnostic imaging."
- Moat: ENDRA's proprietary TAI technology provides a unique imaging solution that is difficult for competitors to replicate quickly.
- growth - Investors looking for high-risk, high-reward opportunities in innovative medical technologies.
- Interest rates affect ENDRA's financing costs for R&D and operational expenses…
- Watch on earnings: Regulatory approval timelines for TAI technology, Clinical trial enrollment and results, Sales growth in TAI systems.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $100.0K to $200.0K as recent clinical trial results showed a 30% improvement in diagnostic accuracy compared to traditional methods.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
Explore More
NDRA Financial Metrics
Explore 130+ historical metrics & ratios
Stock Comparison
Compare equities side by side
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Market Movers
Today's biggest gainers and losers
Market Heatmap
Visual sector performance